RxDoctor Payments Data

Noorun Khan, MD

Internal Medicine · Palos Heights, ILNPI 1548234073

Payments from drug & device makers

$24,552in general payments, 2019–2025

Across 430 payments — averaging $57.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$17K
  • AstraZeneca$1K
  • Pfizer$1K
  • Neurocrine Biosciences, Inc.$484
  • Otsuka America Pharmaceutical, Inc.$463
  • GSK$434
  • plus $4K from 37 others

What the payments were for

  • Speaking & faculty fees$16,76268%
  • Food & beverage$7,78432%
  • Education$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,552 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$1,667,748
Medicare patients
3,278
Services billed
12,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,475$565,168
Invega SustennaPaliperidone Palmitate37$111,957
JardianceEmpagliflozin250$108,405
XareltoRivaroxaban137$62,622
FarxigaDapagliflozin Propanediol90$54,082
OzempicSemaglutide47$53,702
JanuviaSitagliptin Phosphate174$52,628
MyrbetriqMirabegron253$47,441
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$45,820
TradjentaLinagliptin133$43,727
XifaxanRifaximin26$35,204
Atorvastatin Calcium2,708$33,488
TrulicityDulaglutide32$33,011
Breo ElliptaFluticasone/Vilanterol62$32,854
Enoxaparin Sodium221$20,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,049$565,1681,475 claims
Johnson & JohnsonInvega Sustenna, Xarelto, Procrit$307$190,138197 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$84$165,623409 claims
AstraZenecaFarxiga, Brilinta, Lokelma$1,219$82,723231 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta$434$65,431124 claims
Novo NordiskOzempic$212$53,70247 claims
MerckJanuvia$224$52,628174 claims
Astellas Pharma US IncMyrbetriq$138$47,441253 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$15$35,20426 claims
Lilly USA, LLCTrulicity$335$33,01132 claims
Otsuka America Pharmaceutical, Inc.Rexulti$463$17,94222 claims
NovartisEntresto$330$17,69748 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Palos Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →